News
ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC
FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret
